Table 2. Dosing, treatment duration, and modifications.
a
Includes time off drug/interruptions.
b
Based on patients starting each cycle.
c
Three patients received doses >160 mg.
d
Modifications include reductions, interruptions/delays, and re‐escalations; a dose re‐escalation was defined as a dose higher than the previous dose reported or as a dose after a dose interruption (unless a dose reduction was prescribed following an interruption) or as a dose increase after a dose reduction until the protocol dose of 160 mg was reached.
e
Based on the total number of events.
Abbreviations: IQR, interquartile range; SD, standard deviation.